Buccal Insulin Effective in Phase II Trials in Type 2 Diabetics

June, 1999 Toronto, Ontario: Generex Biotechnology Corporation announced some early Phase II results for its orally administered insulin called Oralgen(TM) in the US and Oralin(TM) in Canada. The company has a patented method to deliver Insulin delivery through the inner cheek (buccal) wall via an aerosol applicator. Dr. Marko Mihic at St. Joseph's Hospital in Toronto (in 26 Type 2 patients) reported reduced post meal readings "comparable to injected insulin" which was confirmed (in 10 Type 2 patients) by Arthur Krosnick at some diabetes clinic in Princeton, NJ.

News Top

Home Page
Reload The National Diabetes Center Site